<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704130</url>
  </required_header>
  <id_info>
    <org_study_id>01-16-23B</org_study_id>
    <nct_id>NCT02704130</nct_id>
  </id_info>
  <brief_title>TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma</brief_title>
  <official_title>Transarterial Embolization and Microwave Ablation Combination Therapy in Early-stage Hepatocellular Carcinoma: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolinas Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, prospective randomized controlled trial (RCT) is designed to compare the
      outcomes and clinicopathologic results of trans arterial embolization (TAE) and microwave
      ablation (MWA) combination therapy with MWA monotherapy for the treatment of early (stages 0
      and A) hepatocellular carcinoma (HCC). The primary aim of this study is to test the following
      hypothesis: 2-year intrahepatic disease-free survival does not differ between patients
      receiving the experimental therapy (MWA + TAE) and patients receiving the standard therapy
      (MWA alone) as treatment for early stage HCC. Secondary aims are: 1) to determine the
      clinical feasibility of TAE + MWA in HCC patients with a small tumor burden using patient
      demographics and disease characteristic data and 2) to determine the effect of TAE on
      radiographic tumor characteristics in this patient cohort.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the absence of local or regional recurrence of hepatocellular carcinoma (HCC) as determined by diagnostic imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1, 2, 3, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic disease-free survival</measure>
    <time_frame>1, 2, 3, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality</measure>
    <time_frame>1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatoma</condition>
  <condition>Liver Cancer, Adult</condition>
  <condition>Liver Cell Carcinoma</condition>
  <condition>Liver Cell Carcinoma, Adult</condition>
  <arm_group>
    <arm_group_label>TAE + MWA combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 Âµm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MWA monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transarterial embolization</intervention_name>
    <description>In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.</description>
    <arm_group_label>TAE + MWA combination therapy</arm_group_label>
    <other_name>TAE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave Ablation</intervention_name>
    <description>Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.</description>
    <arm_group_label>TAE + MWA combination therapy</arm_group_label>
    <arm_group_label>MWA monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of hepatocellular carcinoma (HCC)

          -  HCC classification of stage 0 (very early) or stage A (early) according to Barcelona
             Clinic Liver Cancer (BCLC) staging system criteria

          -  Adequate clinical condition to undergo laparoscopic or robot-assisted laparoscopic
             transarterial embolization (TAE) and/or microwave ablation (MWA) as treatment for HCC

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Radiologic (computed tomography or magnetic resonance imaging) evidence of invasion
             into major portal/hepatic venous branches and no extrahepatic metastases

          -  Evidence of residual disease at first post-MWA computed tomography examination

          -  Body Mass Index (BMI) &gt; 35

          -  Previous history of hepatic resections

          -  Severe renal dysfunction (creatinine clearance of &lt;40 mL/min)

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dionisios Vrochides, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiral P Amin, BS</last_name>
      <phone>704-446-4838</phone>
      <email>hiral.amin@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Dionisios Vrochides, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Iannitti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John B Martinie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin H Baker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric A Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott R Broadwell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross J Bellavia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey P Stein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell C Kirks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Embolization</keyword>
  <keyword>Ablation Techniques</keyword>
  <keyword>Transarterial Embolization</keyword>
  <keyword>TAE</keyword>
  <keyword>Microwave Ablation</keyword>
  <keyword>MWA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

